Cargando…
Genomic biomarkers in prostate cancer
Prostate cancer is the most common non-cutaneous cancer among men in the United States. In the last decade there has been a rapid expansion in the field of biomarker assays for diagnosis, prognosis, and treatment prediction in prostate cancer. The evidence base for these assays is rapidly evolving....
Autores principales: | Kornberg, Zachary, Cooperberg, Matthew R., Spratt, Daniel E., Feng, Felix Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043739/ https://www.ncbi.nlm.nih.gov/pubmed/30050804 http://dx.doi.org/10.21037/tau.2018.06.02 |
Ejemplares similares
-
Divorcing Diagnosis From Treatment: Contemporary Management of Low-Risk Prostate Cancer
por: Glass, Allison S., et al.
Publicado: (2013) -
AB004. Rational and risk-stratified prostate cancer screening and treatment
por: Cooperberg, Matthew R.
Publicado: (2018) -
Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes
por: Salciccia, Stefano, et al.
Publicado: (2021) -
Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)
por: Leapman, Michael S., et al.
Publicado: (2017) -
Clinical Applications of Molecular Biomarkers in Prostate Cancer
por: Couñago, Felipe, et al.
Publicado: (2020)